Hybrid opioid/non-opioid ligands in pain research

Current Pharmaceutical Design

Volumn 19, Issue 42, 2013, Pages 7435-7450

  Kleczkowska, Patrycja ^a   Lipkowski, Andrzej W ^a,c   Tourwé, Dirk ^b   Ballet, Steven ^b  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bior multifunctional compounds; Designed multiple ligands; Opioid analgesics; Opioid receptors

Indexed keywords

BRADYKININ; CANNABINOID; CHOLECYSTOKININ; IMIDAZOLINE I2 RECEPTOR; MELANOCORTIN; NEUROTENSIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORNICOTINE; OPIATE; SUBSTANCE P;

ANALGESIC ACTIVITY; ANTINOCICEPTION; ARTICLE; CANCER PAIN; CHRONIC PAIN; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANALGESICS; HUMANS; LIGANDS; OPIOID PEPTIDES; PAIN;

EID: 84891851773     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161281942140105165646     Document Type: Article

References (200)

1. Snyder SH, Pasternak GW. Historical review: Opioid receptors. Trends Pharmacol Sci 2003; 24: 198-205.
2. Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: A review. Adv Ther 2010; 27: 714-30.
3. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Medicine 2009; 10: 654-62.
4. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008; 11: S105-S20.
5. Cochin J, Kornetsky C. Development and loss of tolerance to morphine in the rat after single and multiple injections. J Pharm Exp Ther 1964; 145: 1-20.
6. Delander GE, Takemori AE. Spinal antagonism of tolerance and dependence induced by systemically administered morphine. Eur J Pharmacol 1983; 94: 35-42.
7. Ballet S, Pietsch M, Abell AD. Multiple ligands in opioid research. Prot Pept Lett 2008; 15: 668-82.
8. Lipkowski AW, Misicka A, Carr DB, Rosinsvalle G, Kosson D, Maszczynska Bonney I. Neuropeptide mimetics for pain management. Pure Appl Chem 2004; 76: 941-50.
9. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005; 48: 6523-43.
10. Constantino L, Barlocco D. Designed multiple ligands: basic research vs. clinical outcomes. Curr Med Chem 2012; 19: 3353-87.
11. Gentilucci L. New trends in the development of opioid peptide analogs as advanced remedies for pain relief. Curr Topics Med Chem 2004; 4: 19-38.
12. Morphy R, Rankovic Z. Design of multitarget ligands. In: Rankovic Z, Murphy R. Eds. Lead generation approaches in drug discovery. Wiley & Sons, Inc. Hoboken 2010: 141-64.
13. Rotili D, Tarantino D, Artico M, et al. Diarylpyrimidinedihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level. J Med Chem 2011; 54: 3091-6.
14. Fernandez-Bachiller MI, Perez C, Monjas L, Rademann J, Rodriguez-Franco MI. New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and beta-amyloid-reducing properties. J Med Chem 2012; 55: 1303-17.
15. Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov Today 2007; 12: 156-60.
16. Fujii H. Twin and triplet drugs in opioid research. Top Curr Chem 2011; 299: 239-75.
17. Decker M. Hybrid molecules incorporating natural products: applications in cancer therapy, neurodegenerative disorders and beyond. Curr Med Chem 2011; 18: 1464-85.
18. Davis MP. Opioid receptor targeting ligands for pain management: A review and update. Expert Opin Drug Discov 2010; 5: 1007-22.
19. Lowe JA, Seeger TF, Nagel AA. 1-Naphthylpiperazine derivatives as potential atypical antypsychotic agents. J Med Chem 1991; 34: 1860-6.
20. Hazum E, Chang KJ, Cuatrecasas P. Opiate receptors of neuroblastoma cells: Occurrence in clusters on the cell surface. Science 1979; 206: 1077-9.
21. Ballet S, Marczak ED, Feytens D, et al. Novel multiple opioid ligands based on 4-aminobenzazepinone (Aba), azepinoindole (Aia) and tetrahydroisoquinoline (Tic) scaffolds. Bioorg Med Chem Lett 2010; 20: 1610-3.
22. Parenti C, Turnaturi R, Arico G, et al. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. Life Sci 2010; 90: 957-64.
23. Lee YS, Kulkarani V, Cowell SM, et al. Developments of potent and opioid agonists with high lipophilicity. J Med Chem 2011; 54: 382-6.
24. Lipkowski AW, Carr DB, Bonney I, Misicka A. Biphalin: A multireceptor opioid ligand. In: Chang KJ, Porreca F, Woods JH. Eds. The delta receptor. Marcel Dekker Inc., New York USA, 2004: 221-35.
25. George SR, O'Dowd BF, Lee SP. G protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002; 1: 808-20.
26. Levac BAR, O'Dowd BF, George SR. Oligomerization of opioid receptors: Generation of novel signaling units. Curr Opin Pharmacol 2002; 2: 76-81.
27. Pasternak GW, Pan YX. Mix and match: heterodimers and opioid tolerance. Neuron 2011; 69: 6-8.
28. Del Giudice MR, Borioni A, Bastanzio G, et al. Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor. Eur J Med Chem 2011; 46: 1207-21.
29. B oules M, Fredrickson P, Richelson E. Bioactive analogs of neurotensin: Focus on CNS effects. Peptides 2006; 27: 2523-33.
30. Clineschmidt BV, McGuffin J, Bunting P. Neurotensin: Antinociceptive action in rodents. Eur J Pharmacol 1979; 54: 129-39.
31. Hylden JLK, Wilcox GL. Antinociceptive action of intrathecal neurotensin in mice. Peptides 1983; 4: 517-20.
32. Al-Rodhan NRF, Richelson E, Gilbert JA, et al. Structureantinociceptive activity of neurotensin and some novel analogs in the periaqueductal gray region of the brainstem. Brain Res 1991; 557: 227-35.
33. Smith KE, Boules M, Williams K, Richelson E. NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain. Behav Brain Res 2012; 23: 93-7.
34. Kleczkowska P, Kosson P, Ballet S, et al. PK20, a new opioid neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects. Mol Pain 2010; 6: 86.
35. Hong F, Cusack B, Fauq A, Richelson E. Peptidic and non-peptidic neurotensin analogs. Curr Med Chem 1997; 4: 421-34.
36. St-Gelais F, Jomphe C, Trudeau LE. The role of neurotensin in central nervous system pathophysiology: What is the evidence? J Psychiatry Neurosci 2006; 31: 229-45.
37. Tyler-McMahon BM, Boules M, Richelson E. Neurotensin: Peptide for the next millennium. Reg Peptides 2000; 93: 125-36.
38. Granier C, van Rietschoten J, Kitabgi P, Poustis C, Freychet P. Synthesis and characterization of neurotensin analog for structureactivity relationship studies. Eur J Biochem 1982; 124: 117-25.
39. Garcia-Garayoa E, Bläuenstein P, Bruehlmeier M, et al. Preclinical evaluation of a new stabilized neurotensin(8-13) pseudopeptide radiolabeled with 99mTc. J Nucl Med 2002; 43: 374-83.
40. Kleczkowska P, Bojnik E, Lesniak A, et al. Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20. Pharmacol Rep 2012 (in press).
41. Furst S. Transmitters involved in antinociception in the spinal cord. Brain Res Bull 1999; 48: 129-41.
42. Henry JL. Relation of Substance P to pain transmission: neurophysiological evidence. In: Porter R, O'Connor M. Eds. Substance P in the nervous system. Ciba Found Symp 1982: 206-24.
43. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 1999; 375: 51-60.
44. Zubrzycka M, Janecka A. Substance P: Transmitter of nociception. Endocrine Reg 2000; 34: 195-201.
45. Cridland RA, Henry JL. Facilitation of the tail-flick reflex by noxious cutaneous stimulation in rat: antagonism by a substance P analog. Brain Res 1988; 462: 15-21.
46. Payan DG. Neuropeptides and inflammation: the role of substance P. Ann Rev Med 1989; 40: 341-52.
47. Nieber K, Baumgarten CR, Rathsack R, Furkert J, Oehme P, Kunkel G. Substance P and beta-endorphin-like immunoreactivity in lavage fluids of subjects with and without allergic asthma. J Allergy Clin Immunol 1992; 90: 646-52.
48. McGillis JP, Mitsuhashi M, Payan DG. Immunomodulation by tachykinin neuropeptides. Ann NY Acad Sci 1990; 594: 85-94.
49. Smith HS. Combination opioid analgesics. Pain Physician 2008; 11: 201-14.
50. Kalso E. Improving opioid effectiveness: From ideas to evidence. Eur J Pain 2005; 9: 131-5.
51. King T, Gardell LR, Wang R, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005; 115: 276-88.
52. Yamamoto T, Nair P, Jacobsen NE, et al. Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines. J Med Chem 2010; 53: 5491-501.
53. Yu YJ, Arttamangkul S, Evans Ch, Williams JT, von Zastrow MJ. Neurokinin 1 receptors regulate morphine-induced endocytosis and desensitization of mu opioid receptors in the CNS neurons. J Neurosci 2009; 29: 222-33
54. Lipkowski AW, Carr DB, Misicka A, Misterek. Biological activities of a peptide containing both casomorphin-like and substance P antagonist structural characteristics. In: Brantl V, Teschemacher H. Eds.-Casomorphins and related peptides: recent developments. VCH, Weinheim New York 1994: 113-8.
55. Lipkowski AW, Misterek K. Bifunctional pharmacophores. Biological activities of the peptide analog containing both casomorphin-like and substance P antagonist-like active elements. Pol J Pharmacol Pharm 1992; 44: 25-32.
56. Lipkowski AW, Carr DB, Bonney I, Kosson P. Opioid-Substance P chimeric peptides. In: Kastin AJ. Eds. Handbook of biologically active peptides. Elsevier USA 2006: 1373-7.
57. Maszczynska Bonney I, Foran SE, Marchand JE, Lipkowski AW, Carr DB. Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties. Eur J Pharmacol 2004; 488: 91-9.
58. Lipkowski AW, Misicka A, Carr DB, Ronsisvalle G, Kosson D, Maszczynska Bonney I. Neuropeptide mimetics for pain management. Pure Appl Chem 2004; 76: 941-50.
59. Maszczynska I, Lipkowski AW, Carr DB, Kream RM. Alternative forms of interaction of substance P and opioids in nociceptive transmission. Lett Pept Sci 1998; 5: 395-8.
60. Lipkowski AW, Carr DB. Neuropeptides, peptides and nonpeptide analogs. In: Gutte B. Eds. Peptides: Synthesis, structures and applications. Academic Press, Oxford, UK, 1995: 287-320.
61. MacLeod AM, Merchant KJ, Cascieri MA, et al. N-acyl-L-tryptophan bezyl esters: Potent substance P receptor antagonista. J Med Chem 1993; 36: 2044-5.
62. Largent-Milnes TM, Yamamoto T, Nair P, et al. Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Br J Pharmacol 2010; 161: 986-1001.
63. Yamamoto T, Nair P, Ma S, et al. The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety. Bioorg Med Chem 2009; 17: 7337-43.
64. Yamamoto T, Nair P, Jacobsen NE, et al. The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for/ opioid receptor agonists and neurokinin 1 receptor antagonists. J Med Chem 2008; 51: 6334-47.
65. Hruby VJ. Organic chemistry and biology: Clinical biology through the eyes of collaboration. J Org Chem 2009; 74: 9245-64.
66. Cucumel K, Garreau I, Mery J, et al. Production and characterization of site-directed antibodies against dermorphin and dermorphinrelated peptides. Peptides 1996; 17: 973-82.
67. Millet R, Goossens L, Bertrand-Caumont K, Houssin R, Hénichart JP. Synthesis and biological evaluation of tripeptide derivatives of Cbz-Gly-Leu-Trp-OBzl(CF3)2 as NK1/NK2 ligands. Lett Pept Sci 1999; 6: 255-62.
68. Dickenson AH. Plasticity: implications for opioid and other pharmacological interventions in specific pain states. Behav Brain Sci 1997; 20: 392-403.
69. Chang KJ, Rigdon GC, Howard JL, McNutt RW. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J Pharmacol Exp Ther 1993; 267: 852-7.
70. Rew Y, Malkmus S, Svensson C, et al. Synthesis and biological activities of cyclic lanthionine enkephalin analogs: delta-opioid receptor selective ligands. J Med Chem 2002; 45: 3746-54.
71. Ballet S, Feytens D, Buysse K, et al. Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist. J Med Chem 2011; 54: 2467-76.
72. Tourwé D, Verschueren K, Frycia A, et al. Conformational restriction of Tyr and Phe side-chain in opioid peptides: Information about preferred and bioactive side-chain topologies. Biopolymers 1996; 38: 1-12.
73. Ballet S, Misicka A, Kosson P, et al. Blood-brain barier penetration by two dermorphin tetrapeptide analogs: role of lipophilicity vs structural flexibility. J Med Chem 2008; 51: 2571-4.
74. Guillemyn K, Kleczkowska P, Novoa A, et al. In vivo antinociception of potent mu opioid agonist tetrapeptide analogs and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera. Mol Brain 2012; 5: 4.
75. Balboni G, Marzola E, Sasaki Y, et al. Role of 2',6'-dimethyl-L-tyrosine in some opioid lead compounds. Bioorg Med Chem 2010; 18: 6024-30.
76. 5]enkephalin. J Med Chem 1992; 35: 684-7.
77. Ballet S, Frycia A, Piron J, et al. Synthesis and biological evaluation of constrained analogs of the opioid peptide H-Tyr-D-Ala-PheGly-NH2 using the 4-amino-2-benzazepine-3-one scaffold. J Pept Res 2005; 66: 222-30.
78. Kream RM, Liu NJ, Zhung M, et al. Synthesis and pharmacological analysis of a morphine/substance P chimeric molecule with full analgesic potency in morphine-tolerant rats. Med Sci Monit 2007; 13: BR25-BR31.
79. Vardanyan R, Kumirov VK, Nichol GS, et al. Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands. Bioorg Med Chem 2011; 19: 6135-42.
80. Sancilio FD, Stowell GW, Whittal LB, White D, Whittle RR U.S. Pat 2,005,203,115; Chem Abstract 2005; 143: 311957.
81. Vardanyan R, Vijay G, Nichol GS, et al. Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain. Bioorg Med Chem 2009; 17: 5044-53.
82. Foran SE, CArr DB, Lipkowski AW, et al. Inhibition of morphine tolerance development by a substance P-opioid chimera. J Pharmacol Exp Ther 2000; 259: 1142-8.
83. Lipkowski AW, Osipiak B, Gumulka WS. An approach to the self regulatory mechanism of substance P actions: II. Biological activity of new synthetic peptide analogs related both to enkephalin and substance P. Life Sci 1983; 33 (Suppl 1): 141-4.
84. Foran SE, Carr DB, Lipkowski AW, et al. A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic. Proc Natl Acad Sci USA 2000; 97: 7621-6.
85. Lei SZ, Lipkowski AW, Wilcox GL. Opioid and neurokinin activities of substance P fragments and their analogs. Eur J Pharmacol 1991; 193: 209-15.
86. Vrinten DH, Gispen WH, Groen GJ, Adan RAH. Antagonism of the melanocortin system reduces cold and mechanical allodynia in mononeuropathic rats. J Neurosci 2000; 20: 8131-7.
87. Hruby VJ, Wilkes BC, Hadley ME, et al. Alpha-melanotropinthe minimal active sequence in the frog-skin bioassay. J Med Chem 1987; 30: 2126-30.
88. Haskell-Luevano C, Sawyer TK, Hendrata S, et al. Truncation studies of alpha-melanotropin peptides identify tripeptide analogs exhibiting prolonged agonist bioactivity. Peptides 1996; 17: 995-1002.
89. Koneru A, Satyanarayana S, Rizwan S. Endogenous opioids: Their physiological role and receptors. Global J Pharmacol 2009; 3: 149-53.
90. Wikberg JES, Muceniece R, Mandrika I, et al. New aspects on the melanocortins and their receptors. Pharmacol Res 2000; 42: 393-420.
91. Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB, Elmquist JK. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J Comp Neurol 2003; 457: 213-35.
92. Plantinga LC, Verhaagen J, Edwards PM, Hali M, Brakkee JH, Gispen WH. Pharmacological evidence for the involvement of endogenous alpha-MSH-like peptides in peripheral nerve regeneration. Peptides 1995; 16: 319-24.
93. Bertorelli R, Fredduzzi S, Tarozzo G, et al. Endogenous and exogenous melanocortin antagonists induce anti-allodynic effects in a model of rat neuropathic pain. Behav Brain Res 2005; 157: 55-62.
94. Ercil NE, Galici R, Kesterson RA. HS014, a selective melanocortin-4 (MC4) receptor antagonist, modulates the behavioral effects of morphine in mice. Psychopharmacology (Berl) 2005; 180: 279-85.
95. Starowicz K, Mousa SA, Obara I, et al. Peripheral antinociceptive effects of MC4 receptor antagonists in a rat model of neuropathic painA biochemical and behavioral study. Pharmacol Rep 2009; 61: 1086-95.
96. Bellasio S, Nicolussi E, Bertorelli R, Reggiani A. Melanocortin receptor agonists and antagonists modulate nociceptive sensitivity in the mouse formalin test. Eur J Pharmacol 2003; 482: 127-32.
97. Sandman CA, Kastin KJ. Intraventricular administration of MSH induces hyperalgesia in rats. Peptides 1981; 2: 231-3.
98. Zvejniece L, Muceniece R, Krigere L, Dambrova M, Klusa VZ. The differential influences of melanocortins on nociception in the formalin and tail flick tests. Pharmacol Biochem Behav 2006; 85: 287-91.
99. Wiliams DJW, Lipton JM, Giesecke AHJ. Influence of centrally administered peptides on ear withdrawal from heat in the rabbit. Peptides 1986; 7: 1095-100.
100. Gispen WH, Buitelaar J, Wiegant WM, Terenius L, De Wied D. Interaction between ACTH fragments, brain opiate receptors and morphine-induced analgesia. Eur J Pharmacol 1976; 39: 393-7.
101. Smock T, Fields HL. ACTH1-24 blocks opiate-induced analgesia in the rat. Brain Res 1981; 212: 202-6.
102. Delaney A, Keighren M, Fleetwood-Walker SM, Jackson IJ. Involvement of the melanocortin-1 receptor in acute pain and pain of inflammatory but not neuropathic origin. PLoS ONE 2010; 5: e12498.
103. Wikberg JES. Melanocortin receptors: Perspectives for novel drugs. Eur J Pharmacol 1999; 375: 295-310.
104. Basbaum AI, Fields HL. Endogenous pain control mechanisms: Review and hypothesis. Ann Neurol 1978; 4: 451-62.
105. Gosselin RD, Suter MR, Ji RR, Decosterd I. Glial cells and chronic pain. Neuroscientist 2010; 16: 519-31.
106. Xia Y, Wikberg JES, Chhajlani V. Expression of melanocortin 1 receptor in periaqueductal gray matter. Neuroreport 1995; 6: 2193-6.
107. Mogil JS, Wilson SG, Chesler EJ, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 2003; 100: 4867-72.
108. Besse D, Lombard MC, Zajac JM, Roques BP, Besson JM. Preand postsynaptic distribution of, and opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res 1990; 521: 15-22.
109. Moskowitz AS, Goodman RR. Autoradiographic distribution of mu1 and mu2 opioid receptor binding in the mouse central nervous system. Brain Res 1985; 360: 117-29.
110. Han G, Quillan JM, Carlson K, Sadeé, Hruby VJ. Design of novel chimeric melanotropin-deltorphin analogs. Discovery of the first potent human melanocortin 1 receptor antagonist. J Med Chem 2003; 46: 810-9.
111. Kulkarni VV, Lee YS, Salibay C, et al. Novel analogs of bifunctional ligands for opioid and melanocortin 4 receptor. Adv Exp Med Biol 2009; 611: 195-6.
112. Al-Obeidi F, Castrucci AMD, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogs of alpha-melanotropindesigned based on molecular dynamics. J Med Chem 1989; 32: 2555-61.
113. Al-Obeidi F, O'Connor SD, Job C, Hruby VJ, Pettitt BM. NMR and quenched molecular dynamics studies of superpotent linear and cyclic alpha-melanotropins. J Pept Res 1998; 51: 420-31.
114. Knittel JJ, Sawyer TK, Hruby VJ, Hadley ME. Structure-activity studies of high potent [Cys4, Cys10]melanotropin analogs. J Med Chem 1983; 28: 125-9.
115. Beglinger C. Effect of cholecystokinin on gastric motility in humans. Ann NY Acad Sci 1994; 713: 219-25.
116. Liddle RA. Integrated actions of cholecystokinin on the gastrointestinal tract: Use of the cholecystokinin bioassay. Gastroenterol Clin North Am 1989; 18: 735-56.
117. Faris PL. Role of cholecystokinin in the control of nociception and food intake. Prog Clin Biol Res 1985; 192: 159-66.
118. Wiesenfeld-Hallin Z, Xu X-J. The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance. Reg Peptides 1996; 65: 23-8.
119. Faris PL, Komisaruk BR, Watkins LR, Mayer DJ. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983; 219: 310-2.
120. Itoh S, Katsuura G, Maeda Y. Caerulein and cholecystokinin suppress beta-endorphininduced analgesia in the rat. Eur J Pharmacol 1982; 80: 421-5.
121. Dourish CT, Hawley D, Iversen SD. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur J Pharmacol 1988; 147: 469-72.
122. McCleane G. Cholecystokinin and its antagonists in pain management. The Haworth Press, NY 2006: 1-145.
123. Watkins LR, Kinscheck IB, Mayer DJ. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by Proglumide. Science 1984; 224: 395-6.
124. Agnes RS, Lee YS, Davis P, et al. Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem 2006; 49: 2868-75.
125. Hruby VJ, Agnes RS, Davis P, et al. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci 2003; 73: 699-704.
126. Lee YS, Fernandes S, Kulkarni V, et al. Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain. Bioorg Med Chem Lett 2010; 20: 4080-4.
127. Zheng Y, Akgün E, Harikumar KG, et al. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. J Med Chem 2009; 52: 247-58.
128. Slaninova J, Knapp RJ, Wu JJ, et al. Opioid receptor binding properties of analgesics of cholecystokinin octapeptide. Eur J Pharmacol 1991; 200: 195-8.
129. Chang JK, Fong BT, Pert A, Pert CB. Opiate receptor affinities and behavioral effects of enkephalin: structural-activity relationship of ten synthetic peptide analogs. Life Sci 1976; 18: 1473-81.
130. Morgan BA, Smith CF, Waterfield AA, Hughes J, Kosterlitz HW. Structure-activity relationships of methionine-enkephalin. J Pharm Pharmacol 1976; 28: 660-1.
131. Takeda Y, Hoshino M, Yanaihara N, et al. Comparison of CCK-8 receptors in the pancreas and brain of rats using CCK-8 analogs. Jap J Pharmacology 1989; 49: 471-81.
132. Lu L, Huang M, Liu A, Ma L. Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats. Neuroreport 2000; 11: 829-32.
133. Suberg SN, Culhane ES, Carstens E, Watkins LR. The potentiation of morphine-induced inhibition of spinal transmission by proglumide, a putative cholecystokinin antagonist. Ann NY Acad Sci 1985; 448: 660-2.
134. Boteju LW, Nikiforovich GV, Haskell-Luevano C, et al. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analog that binds to both CCK-B and-opioid receptors. J Med Chem 1996; 39: 4120-4.
135. Adachi H, Rajh HM, Tesser GI, De Pont JJHHM, Jensen RT, Gardner JD. Interaction of tryptophan-modified analogs of cholecystokinin octapeptide with cholecystokinin receptors on pancreatic acini. Biochim Biophys Acta 1981; 678: 358-63.
136. Agnes RS, Ying J, Kövér KE, et al. Structure-activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. Peptides 2008; 29: 1413-23.
137. Martinez J, Rodriguez M, Lignon MF, et al. Structure activity relationship of cholecystokinin: Analogs exhibiting selective activity. J Pharm Belg 1991; 46: 9-16.
138. Hanlon KE, Herman DS, Agnes RS, et al. Novel peptide ligands with dual acting pharmacophores designed for the pathophysilogy of neuropathic pain. Brain Res 2011; 1395: 1-11.
139. Hruby VJ, Porreca F, Yamamura HI, et al. New paradigms and tools in drug design for pain and addiction. AAPS J 2006; 8: E450-E460.
140. Ferrari F, Fiorentino S, Mennuni L, et al. Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. J Pain Res 2011; 4: 111-25.
141. Fairbanks CA, Schreiber KL, Brewer KL, et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA 2000; 97: 10584-9.
142. Jett MF, Hedley LR, Dillon MP, Eglen RM, Hunter JC. Behavioral effects of RS-45041-190, a selective I2 imidazoline ligand, in rats. Ann NY Acad Sci 1999; 881: 369-71.
143. Thorn DA, Zhang Y, Peng BW, Winter JC, Li JX. Effects of imidazoline I2 receptor ligands on morphineand tramadol-induced antinociception in rats. Eur J Pharmacol 2011; 670: 435-40.
144. Sanchez-Blazquez P, Boronat MA, Olmos G, Garcia-Sevilla JA, Garzon J. Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: A model to detect agonist and antagonist activities at these receptors. Br J Pharmacol 2000; 130: 146-52.
145. Yesilyurt O, Uzbay IT. Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacol 2001; 25: 98-103.
146. Kolesnikow YS, Pasternak J, Pasternak GW. Modulation of opioid analgesia by agmatine. Eur J Pharmacol 1996; 296: 17-22.
147. Roerig SC. Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception. Ann NY Acad Sci 2003; 1009: 116-26.
148. Li JX, Zhang Y. Imidazoline I2 receptors: Target for new analgesics? Eur J Pharmacol 2011; 658: 49-56.
149. Montero A, Goya P, Jagerovic N, et al. Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for opioid and I2-imidazoline receptors: synthesis an pharmacological screening. Bioorg Med Chem 2002; 10: 1009-18.
150. Dardonville C, Fernandez-Fernandez C, Gibbson SL, et al. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the-opioid receptor and I2-imidazoline binding sites. Bioorg Med Chem 2006; 14: 6570-80.
151. Holdcroft A, Smith A, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997; 52: 483-6.
152. Manzanares J, Corchero J, Romero J, Fernández-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-94.
153. Patacchioli RF. Neuropharmacology of cannabinoid system. From basic science to clinical applications. Curr Neuropharmacology 2004; 2: 1-7.
154. Viganò D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoids and opioid interactions. Pharmacol Biochem Behav 2005; 81: 360-8.
155. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-70.
156. Manzanares J, Julian MD, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 2006; 4: 239-57.
157. Cichewicz DL, Martin ZL, Smith FL, Welch SP. Enhancement mu opioid antinociception by oral delta 9-tetrahydrocannabinol: doseresponse analysis and receptor identification. J Pharmacol Exp Ther 1999; 289: 859-67.
158. Smith FL, Cichewicz D, Martin ZL, Welch SP. The enhancement of morphine antinociception in mice by delta 9tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 60: 559-66.
159. Welch SP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry 2009; 21: 143-51.
160. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002; 22: 1146-54.
161. Valverde O, Ledent C, Beslot F, Parmentier M, Roques BP. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 2000; 12: 533-9.
162. Hohmann AG, Briley EM, Miles H. Preand postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999; 822: 17-25.
163. Reche I, Fuentes JA, Ruiz-Gayo M. Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of muand kappa-opioid receptors. Eur J Pharmacol 1996; 318: 11-6.
164. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74: 1317-24.
165. Holtman JR, Crooks PE, Dhooper H, Inventors; University of Kentucky, assignee. Novel synergistic opioid-cannabinoid codrug for pain management. United States Patent 20080176885.
166. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32: 1-46.
167. Regoli D, Nsa Allogho S, Rizzi A, Gobeil FJ. Bradykinin receptors and their antagonists. Eur J Pharmacol 1998; 348: 1-10.
168. Steranka LR, Manning DC, DeHaas CJ, et al. Bradykinin is a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc Natl Acad Sci USA 1988; 85: 3245-9.
169. Tonussi CR, Ferreira SH: Bradykinin-induced knee joint incapacitation involves bradykinin B2 receptor mediated hyperalgesia and bradykinin B1 receptor-mediated nociception. Eur J Pharmacol 1997; 326: 61-5.
170. Kaufman GN, Zaouter C, Valteau B, Sirois P, Moldovan F. Nociceptive tolerance is improved by bradykinin receptor B1 antagonism and joint morphology is protected by both endothelin type A and bradykinin receptor B1 antagonism in a surgical model of osteoarthritis. Arth Res Ther 2011; 13: R76.
171. Cheronis JC, Blodgett JK, Goodfellow VS, Marathe MV, Spruce LV, Whalley ET, Inventors; Cortech Inc., assignee. Bradykinin antagonists. United States Patent 005863899.
172. Deekonda S, Rankine D, Davis P, Lai J, Porreca F, Hruby VJ. Design and synthesis of novel bifunctional ligands (opioid agonist and bradykinin antagonist) for treatment of chronic and neuropathic pain. 22nd American Peptide Symposium, San Diego, California, United States, June 25-30, 2011, pp. 358-9.
173. Lain KY, Powers RW, Krohn MA, Ness RB, Crombleholme WR, Roberts JM. Urinary nicotine concentration confirms the reduced risk of preeclampsia with tobacco exposure. Am J Obstet Gynecol 1991; 181: 1192-6.
174. Hjern A, Hedberg A, Haglund B, Rosen M. Does tobacco smoke prevent atopic disorders? A study of two generations of Swedish residents. Clin Exp Allergy 2001; 31: 908-14.
175. Fagerström KO, Pomerleau O, Giordani B, Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacol 1994; 116: 117-9.
176. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacol 1998; 138: 217-30.
177. Powledge TM. Nicotine as therapy. PloS Biol 2004; 2: e404.
178. Aceto MD, Awaya H, Martin BR, May EL. Antinociceptive action of nicotine and its methiodine derivatives in mice and rats. Br J Pharmacol 1983; 79: 869-76.
179. Sahley TL, Berntson GG. Antinociceptive effects of central and systemic administrations of nicotine in the rat. Psychopharmacol 1979; 65: 279-83.
180. Tripathy HL. Nicotine-induced antinociception in rats and mice: Correlation with nicotine brain levels. J Pharmacol Exp Ther 1982; 221: 91-6.
181. Badio B, Daly JW. Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol 1994; 45: 563-9.
182. Bannon AW, Gunther KL, Decker MW. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effect of (±)-epibatidine. Pharmacol Biochem Behav 1995; 51: 693-8.
183. Damaj MI, Martin BR. Tolerance to the antinociceptive effect of epibatidine after acute and chronic administration in mice. Eur J Pharmacol 1996; 300: 51-7.
184. Sullivan JP, Decker MW, Brioni JD, et al. (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1994; 271: 624-31.
185. Traynor JR. Epibatidine and pain. Br J Anaesth 1998; 81: 69-76.
186. Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, et al. ABT-594 (R)-5-(2-azetidinylmethoxy)-2-chloropyridine: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. J Pharmacol Exp Ther 1998; 285: 777-86.
187. Decker M W, Bannon AW, Buckley MJ, et al. Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice. Eur J Pharmacol 1998; 346: 23-33.
188. Bonhaus DW, Bley KR, Broka CA, et al. Characterization of the electrophysiological, biochemical and behavioral actions of epibatidine. J Pharmacol Exp Ther 1995; 272: 1199-203.
189. Boyce S, Webb KJ, Shepheard SL, Russell MGN, Hill RG, Rupniak NMJ. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. Pain 2000; 85: 443-50.
190. Siminszky B, Gavilano L, Bowen SW, Dewey RE. Conversion of nicotine to nornicotine in Nicotiana tabacum is mediated by CYP82E4, a cytochrome P450 monooxygenase. Proc Natl Acad Sci USA 2005; 102: 14919-24.
191. Abdin MJ, Morioka N, Morita K, et al. Analgesic action of nicotine on tibial nerve transection (TNT)-induced mechanical allodynia through enhancement of the glycinergic inhibitory system in spinal cord. Life Sci 2006; 80: 9-16.
192. Cordero-Erausquin M, Marubio LM, Klink R, Changeux JP. Nicotinic receptor function: new perspectives from knockout mice. Trends Pharmacol Sci 2000; 21: 211-7.
193. Damaj MI, Meyer EM, Martin BR. The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology 2000; 39: 2785-91.
194. Lawand NB, Lu Y, Westlund KN. Nicotinic cholinergic receptors: Potential taregets for inflammatory pain relief. Pain 1999; 80: 291-9.
195. Holtman JR, Crooks PA, Johnson-Hardy JK, Wala EP. The analgesic and toxic effects of nornicotine enantiomers alone and in interaction with morphine in rodent models of acute and persistent pain. Pharmacol Biochem Behav 2010; 94: 352-62.
196. Holtman JR, Crooks PA, Chakraborty U inventors; University of Kentucky, assignee. Opioid-nornicotine codrugs combinations for pain management. United States Patent 20110112130.
197. Morphy R. The influence of target family and functional activity on the physiochemical properties of pre-clinical compounds. J Med Chem 2006; 49; 2969-78.
198. Portoghese PS, Larson DL, Sayre LM, et al. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J Med Chem 1986; 29: 1855-61.
199. Pasternak GW. Preclinical pharmacology and opioid combinations. Pain Med 2012; 13: S4-S11.
200. Tumati S, Largent-Milnes T, Keresztes AI, et al. Tachykinin NK1 receptor antagonist co-administration attenuates opioid withdrawalmediated spinal microglia and astrocyte activation. Eur J Pharmacol 2012; 684: 64-70.